Treatment for Henoch-Schönlein Purpura (HSP)
Most HSP cases are self-limiting and require only supportive care; corticosteroids should be reserved for severe gastrointestinal symptoms or significant renal involvement, not used prophylactically. 1, 2
Initial Management Approach
The primary treatment strategy for HSP depends on disease severity and organ involvement. Since 94% of children and 89% of adults experience spontaneous resolution, aggressive immunosuppression is not warranted in uncomplicated cases 2, 3.
Mild Disease (Skin and Joint Involvement Only)
- Supportive care alone is appropriate
- NSAIDs for arthralgia (monitor renal function)
- Adequate hydration
- Rest during acute phase
- Do not use prophylactic corticosteroids - evidence shows they do not prevent renal complications 1, 2
Moderate to Severe Gastrointestinal Involvement
When patients present with severe abdominal pain or gastrointestinal hemorrhage:
- Oral prednisone 1-2 mg/kg/day for 2 weeks 3
- This reduces the mean time to resolution of abdominal pain 3
- Taper over 2-4 weeks once symptoms improve
- Consider hospitalization for severe bleeding or suspected intussusception
Important caveat: While corticosteroids effectively treat GI symptoms, they do not prevent the development of nephropathy 1.
Renal Involvement Management
Renal disease occurs in 40-50% of HSP patients and determines long-term prognosis 3. Adults have higher rates of severe nephritis than children 4.
Mild Nephritis (Microscopic Hematuria, Proteinuria <1g/day)
- ACE inhibitor or ARB to prevent secondary glomerular injury 1
- Close monitoring of proteinuria and renal function
- No immunosuppression needed initially
Moderate Nephritis (Proteinuria 1-3g/day, Normal Renal Function)
- Oral prednisone 1 mg/kg/day (maximum 60-80 mg/day)
- Continue until proteinuria improves, then taper over 2-3 months
- Add ACE inhibitor or ARB for renoprotection 1
Severe Nephritis (Crescentic GN, Rapidly Progressive GN, Nephrotic Syndrome)
For patients with biopsy-proven crescentic nephritis or rapidly declining renal function:
- IV methylprednisolone pulses 500-750 mg for 3 consecutive days 5
- Followed by oral prednisone 1 mg/kg/day, tapering to ≤10 mg/day by 4-6 months 5
- Plus cyclophosphamide (oral 2 mg/kg/day or IV pulses) for 3-6 months 6
- Alternative: Mycophenolate mofetil 2-3 g/day if cyclophosphamide contraindicated 4
- Consider plasmapheresis in life-threatening cases 6
Emerging evidence: Rituximab has shown efficacy in reducing relapse frequency and achieving long-term remission in refractory cases 4.
Monitoring Requirements
All HSP patients require 6 months minimum follow-up to assess for disease relapse or late-onset nephritis 2:
- Weekly urinalysis and blood pressure for first month
- Monthly for 3 months
- Every 3 months for remainder of first year
- Check: urinalysis, urine protein-creatinine ratio, serum creatinine, blood pressure
Common Pitfalls to Avoid
- Do not use prophylactic steroids in uncomplicated HSP - systematic reviews show no benefit in preventing complications 2
- Do not delay renal biopsy in patients with nephrotic-range proteinuria, declining GFR, or persistent hematuria beyond 3 months
- Do not stop monitoring at clinical resolution - nephritis can develop or relapse months after initial presentation 2
- Adults require more aggressive monitoring and treatment than children due to higher complication rates 4
Prognosis
Long-term outcome depends entirely on renal involvement severity. End-stage renal disease occurs in 1-5% of patients 3. Patients with isolated skin and joint manifestations have excellent prognosis with supportive care alone.